Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
Status:
Active, not recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour
burden it should be effective in primarily treated intermediate and high risk prostate cancer
as an adjuvant treatment after radiotherapy to prevent early relapse. This will therefore be
tested in a randomised phase III trial where patients will be randomized either to docetaxel
or surveillance